TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07354659: A Randomized, Blinded, Placebo- and Active-Controlled, Adaptive Phase 2 Study to Evaluate the Immunogenicity and Safety of SYS6017 (a Herpes Zoster mRNA Vaccine) in Healthy Participants Aged 40 Years and Above

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 800 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07354659 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07354659 Rescue Dossier →